Kent-Athlone Pharma Group

Canaccord Genuity has advised Kent-Athlone Pharma Group, a portfolio company of Duke Street on the sale of Athlone Laboratories, to Gaelic Laboratories

Canaccord Genuity is pleased to announce that it has advised Kent-Athlone Pharma Group, a European specialty pharmaceutical company, and portfolio company of Duke Street on the divestment of Athlone Laboratories Limited, an Irish manufacturer of oral antibiotic finished dosage forms (FDFs), from Linnum Holdings (a group company within Kent-Athlone Pharma Group) to Gaelic Laboratories.

Athlone Laboratories currently manufactures semi-synthetic penicillins (SSPs) with expertise in critical oral antibiotic formulations, including amoxicillin capsules and powders for oral suspension (POS), flucloxacillin capsules and POS, and penicillin tablets. The Athlone Laboratories site currently serves customers in Ireland, the United Kingdom, Europe (Netherlands, Belgium, Germany), and other international markets.

Kent-Athlone Pharma Group will continue to market the products manufactured and supplied by Athlone Laboratories (now part of Gaelic Laboratories) primarily in the UK and Ireland.